[{"id":"8c941601-ba20-47c7-a04d-a7b15996afd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014658","created_at":"2023-08-28T14:08:42.615Z","updated_at":"2025-02-25T14:18:12.807Z","phase":"Phase 1/2","brief_title":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT06014658","lead_sponsor":"MBrace Therapeutics","biomarkers":" HER-2 • EPHA5","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • EPHA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MBRC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-18"}]